Cycle Group Holdings Limited has reached a definitive agreement to acquire Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on treatments for rare diseases. Under the agreement, Cycle will launch a tender offer to purchase all outstanding shares of Applied Therapeutics for $0.088 per share in cash at closing, along with one non-transferrable contingent value right $(CVR)$ per share, which may provide additional payments based on future milestones. The boards of both companies have approved the transaction, which is expected to close in the first quarter of 2026, subject to customary closing conditions. Applied Therapeutics' lead drug candidate, govorestat, is being developed for several rare central nervous system metabolic diseases.